Terrance Mcguire Sells 83,817 Shares of Invivyd, Inc. (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 83,817 shares of the company’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $0.54, for a total transaction of $45,261.18. Following the sale, the director now owns 3,340,520 shares in the company, valued at $1,803,880.80. This represents a 2.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Terrance Mcguire also recently made the following trade(s):

• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The shares were sold at an average price of $0.45, for a total value of $34,099.20.
• On Friday, December 20th, Terrance Mcguire sold 119,805 shares of Invivyd stock. The stock was sold at an average price of $0.42, for a total value of $50,318.10.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total value of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total transaction of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00.

Invivyd Stock Performance

Invivyd stock opened at $0.51 on Friday. The company has a market capitalization of $61.00 million, a PE ratio of -0.26 and a beta of 0.53. The company has a 50 day moving average price of $0.73 and a 200-day moving average price of $0.97. Invivyd, Inc. has a fifty-two week low of $0.40 and a fifty-two week high of $5.20.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a research note on Thursday, November 21st. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Morgan Stanley dropped their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Finally, HC Wainwright decreased their target price on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $7.89.

Institutional Investors Weigh In On Invivyd

Institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC grew its position in shares of Invivyd by 198.6% during the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after buying an additional 25,201 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Invivyd during the 2nd quarter valued at about $263,000. Rhumbline Advisers raised its holdings in shares of Invivyd by 4,434.1% in the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock valued at $92,000 after purchasing an additional 82,164 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Invivyd by 232.0% in the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after purchasing an additional 474,301 shares during the period. Finally, Cornercap Investment Counsel Inc. bought a new position in shares of Invivyd during the second quarter valued at approximately $86,000. 70.36% of the stock is owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.